

organized by:



in collaboration with:



under the auspices of:



# MELANOMA bridge 2020

Virtual meeting  
December 3<sup>rd</sup> - 5<sup>th</sup>, 2020

# GENERAL INFORMATION

---



## CME PROVIDER AND ORGANIZING AGENCY:

3P Solution Srl

Via Marradi 3, 20123 Milan

Phone +39 02 36631574 | Fax +39 02 36631640

Cell. +39 391 4986841

[www.3psolution.it](http://www.3psolution.it)

[info@3psolution.it](mailto:info@3psolution.it)

[info@melanomabridge.org](mailto:info@melanomabridge.org)

## OFFICIAL LANGUAGE:

The official language is English

## REGISTRATION:

This year the registration will be **free of charge** for all HCPs, but only registered attendees will be admitted to the meeting.

To register:

- go to: [www.melanomabridge.org/registration-key-dates.php](http://www.melanomabridge.org/registration-key-dates.php) and click on REGISTER NOW
- directly through the link: [www.vincentonair.com](http://www.vincentonair.com)

Please, contact the Organizing Secretariat for any further information:  
[registration@melanomabridge.org](mailto:registration@melanomabridge.org)

# SCIENTIFIC RATIONAL

---

Recent insights into the genetic and somatic aberrations have initiated a new era of rapidly evolving treatments for melanoma.

The possibility to use targeted and immune-based drugs alone, in combination, or in sequence, able to improve responses to overcome the resistance, to potentiate the action of immune system with the new immunomodulating antibodies, and identification of biomarkers that can predict the response to a particular therapy, represent actual concepts and approaches in the clinical management of melanoma.

Melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival.

Since then, improved understanding of the tumor microenvironment and tumor immune-evasion strategies has resulted in different approaches to target and harness the immune response.

Approval of new immune- and target-therapies have further improved outcomes for patients with advanced melanoma.

The therapies offer the opportunity for various approaches with distinct modes of action being used in combination with one another, as well as combined with other treatment modalities such as radiotherapy, electrochemotherapy and surgery.

Latest findings in melanoma research and advances on themes of paramount importance for melanoma prevention, diagnosis and treatment, will be discussed in the session dedicated to system biology on immunotherapy, immunogenicity and gene expression profiling, in the two sessions focused on the progresses of melanoma research on biomarkers/precision medicine and on combination strategies, respectively.

Conclusions will be drawn after the "Great Debate" session, where counterpoint views from leading experts on specific controversial clinical issues will be presented and discussed from different points of view:

- Is innate immunity important: yes or not?
- Does AJCC classification an improvement for better stadiation: yes or not?
- Is the sentinel node biopsy useful for staging patient: yes or not?
- Triplette combination (target therapy plus IO) VS combo IO
- Neoadjuvant or adjuvant therapy: which is better?

In order to disclose and stimulate the discussion of new approaches and strategies in the field of melanoma and, based on the increasing success of "Melanoma Bridge" events over the years since 2011, a panel of international faculty will join the congress that will be held as webinar in December 2020.

# PRELIMINARY SCIENTIFIC PROGRAM

Thursday, Dec 3<sup>rd</sup>, 2020



## **MELANOMA BRIDGE OPENING SESSION\*\***

*Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov*

09:20 pm Anti-cancer responses to the spectrum of "Cancer Antigens" and immune contraction\*\*

**Bernard A. Fox**

09:40 pm The immune contexture for survival and immunotherapy response\*\*

**Jerome Galon**

2020

# PRELIMINARY SCIENTIFIC PROGRAM

Friday, Dec 4<sup>th</sup>, 2020



12:30 pm	Introduction and objectives <b>Paolo A. Ascierto</b>
	<b>SESSION</b> <b>MELANOMA AS A MODEL SYSTEM</b> <i>Chairpersons: Giuseppe Masucci, Magdalena Thurin</i>
12:40 pm	Targeting the microbiota in melanoma anti-PD1 therapy <b>Giorgio Trinchieri</b>
12:55 pm	Prediction of response to check point inhibition: is there a simple but not simplistic way? <b>Iman Osman</b>
01:10 pm	Immunotherapy-induced anti-cancer responses <b>Bernard A. Fox</b>
01:25 pm	The role of CD39 in melanoma <b>Michele Teng</b>
01:40 pm	Discussion on Melanoma as a model system <b>Giuseppe Masucci, Magdalena Thurin</b>
01:55 pm	Break**
02:25 pm	Extending Sir James Black's 1963 invention and 1988 Nobel award winning discovery Propranolol as an immune checkpoint inhibitor: Update of a phase I trial of propranolol plus pembrolizumab <b>Marc Ernstoff</b>
02:40 pm	Escape mechanisms in melanoma <b>Soldano Ferrone</b>
02:55 pm	Electrochemotherapy in metastatic melanoma <b>Corrado Caracò</b>
03:10 pm	Uveal Melanoma <b>Richard D. Carvajal</b>
03:25 pm	Discussion on Melanoma as a model system <b>Giuseppe Masucci, Magdalena Thurin</b>
03:40 pm	<b>SYMPOSIUM</b> Target therapy in Melanoma The future of targeted therapy is immunotherapy <b>Paul Nathan</b> <b>Paolo A. Ascierto</b>
04:30 pm	Break**

\*\*Not included in the CME accredited program

# PRELIMINARY SCIENTIFIC PROGRAM

Friday, Dec 4<sup>th</sup>, 2020



## SESSION 3

### MECHANISMS OF RESISTANCE AND DRIVERS OF RESPONSE

*Chairpersons: Paolo A. Ascierto, Gerardo Botti, Giuseppe Palmieri*

- |          |  |
|----------|--|
| 04:45 pm | <b>SYMPOSIUM</b> Adjuvant Therapy<br>Adjuvant therapy in melanoma: maximizing the chances for a cure<br><b>Olivier Michielin</b><br><b>Paolo A. Ascierto</b> |
| 05:35 pm | Translational research in the metastatic melanoma<br><b>Reinhard Dummer</b>  |
| 05:50 pm | Intrinsic tumor genomic and metabolic factors<br><b>Patrick Hwu</b>  |
| 06:05 pm | Achieving durable MAPK Suppression and Invigorating Anti-melanoma T Cell Immunity<br><b>Roger Lo</b>   |
| 06:20 pm | Break**  |
| 06:35 pm | Tumor mutation burden and liquid biopsies<br><b>Claus Garbe</b>  |
| 06:50 pm | Mechanisms of resistance to cancer immunotherapy<br><b>Thomas F. Gajewski</b>  |
| 07:05 pm | T-cell intrinsic mechanisms of resistance to PD1 checkpoint blockade<br><b>Michelle Krogsaard</b>  |
| 07:20 pm | Targeting dendritic cells to enhance the effectiveness of PD1 blockade against cold tumors<br><b>Pawel Kalinski</b>  |
| 07:35 pm | Discussion on Mechanisms of resistance and drivers of response<br><b>Paolo A. Ascierto, Gerardo Botti, Giuseppe Palmieri</b>                                 |

# PRELIMINARY SCIENTIFIC PROGRAM

Saturday, Dec 5<sup>th</sup>, 2020



## SESSION

### EMERGENT STRATEGIES

*Chairpersons: Alexander M. Eggermont, Alessandro Testori*

- |          |   |
|----------|---|
| 12:30 am | <b>SYMPOSIUM</b> IO and adjuvant therapy in melanoma<br>Adjuvant immunotherapy in melanoma: current practice and future directions<br><b>Georgina V. Long</b><br><b>Paolo A. Ascierto</b> |
| 01:20 pm | Neoadjuvant Immunotherapy - less is more<br><b>Christian Blank</b>  |
| 01:35 pm | What are new ways to think about immunotherapy combinations for melanoma?<br><b>Michael A. Postow</b>   |
| 01:50 pm | Considering QUAD therapy to address unmet needs in high risk BRAF mutant melanoma<br><b>Jason Luke</b>  |
| 02:05 pm | Break**   |
| 02:20 pm | Development of novel antibodies targeting regulatory T cells in cancer<br><b>Sergio Quezada</b>   |
| 02:35 pm | Oncolytic virus combo with CKI- Ipi talimogene laherparepvec and talimogene laherparepvec+Pembrolizumab<br><b>Igor Puzanov</b>  |
| 02:50 pm | Exploring the potential of dendritic cell therapy for the treatment of advanced melanoma, from moDC to myDC<br><b>Bart Neyns</b>  |
| 03:05 pm | Discussion on Emergent strategies<br><b>Alexander M. Eggermont, Alessandro Testori</b>  |
| 03:35 pm | Break**   |

# PRELIMINARY SCIENTIFIC PROGRAM

Saturday, Dec 5<sup>th</sup>, 2020



## SESSION

### GREAT DEBATE

*Chairpersons: Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov*

- 03:50 pm Is innate immunity important: yes or no?  
**Jeffrey S. Weber, Alexander M. Eggermont**
- 04:20 pm Discussion on "Is innate immunity important: yes or no?"  
**Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov**
- 04:30 pm Does AJCC classification an empovement for better stadiation: yes or no?  
**Jeffrey E. Gershenwald, Jean-Jacques Grob**
- 05:00 pm Discussion on "Does AJCC classification an empovement for better stadiation: yes or no?"  
**Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov**
- 05:10 pm Break\*\*
- 05:25 pm Is the sentinel node biopsy useful for staging patient: yes or no?  
**Vernon K. Sondak, Jean-Jacques Grob**
- 05:55 pm Discussion on "Is the sentinel node biopsy useful for staging patient: yes or no?"  
**Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov**
- 06:05 pm Triplette combination (target therapy plus IO) VS combo IO  
**Jeffrey A. Sosman, Michael B. Atkins**
- 06:35 pm Discussion on "Triplette combination (target therapy plus IO) VS combo IO"  
**Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov**
- 06:45 pm Break\*\*
- 07:00 pm Neoadjuvant or adjuvant therapy: which is better?  
**Hussein A. Tawbi, Omid Hamid**
- 07:30 pm Discussion on "Neoadjuvant or adjuvant therapy: which is better?"  
**Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov**
- 07:40 pm What we will do on Monday?  
**Sanjiv S. Agarwala**
- 07:55 pm Conclusions  
**Paolo A. Ascierto, Corrado Caracò, Iman Osman, Igor Puzanov**




# PRESIDENCY

---

**Paolo A. Ascierto**

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute Fondazione "G. Pascale", Naples, Italy

**Corrado Caracò**

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Iman Osman**

Associate Dean for Translation Research and Director of the Melanoma Program, New York University Langone, Medical School, New York City, New York, US

**Igor Puzanov**

Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, US

# SCIENTIFIC BOARD

**Sanjiv S. Agarwala**

Professor & Chief, Haematology & Oncology, St Luke's University Hospital and Temple University, Bethlehem, PA, US

**Paolo A. Ascierto**

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute Fondazione "G. Pascale", Naples, Italy

**Carlo Bifulco**

Medical Director of Oncological Molecular Pathology and Pathology Informatics, Providence Oregon Regional Laboratory and Earle A. Chiles Research Institute, Portland, Oregon, US

**Elizabeth M. Burton**

Director, Melanoma Research Planning & Development, The University of Texas MD Anderson Cancer Center, Houston, TX, US

**Lisa H. Butterfield**

Research Center Vice President, Parker Institute for Cancer Immunotherapy and Adjunct Professor of Microbiology and Immunology, University of California, San Francisco, California, US

**Corrado Caracò**

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Sandra Demaria**

Professor of Pathology and Laboratory Medicine, Professor of Radiation Oncology and Adjunct Professor at Department of Pathology, Weill Cornell Medical College and NYU School of Medicine, New York City, New York, US

**Reinhard Dummer**

Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

# SCIENTIFIC BOARD

---

**Bernard A. Fox**

Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, Oregon, US

**Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

**Claus Garbe**

University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology, Eberhard- Karls University Tuebingen, Germany

**Omid Hamid**

Chief of Research/ Immuno-Oncology and Co-Director, Cutaneous Malignancy Program, The Angeles Clinic and Research Institute, Los Angeles, California, US

**Patrick Hwu**

MD, President & CEO, Moffitt Cancer Center, Tampa, Florida, US

**Giuseppe Masucci**

Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

**Iman Osman**

Associate Dean for Translation Research and Director of the Melanoma Program, New York University Langone, Medical School, New York City, New York, US

**Giuseppe Palmieri**

President Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy

**Michael A. Postow**

Memorial Sloan Kettering Cancer Center, New York City, New York, US

**Igor Puzanov**

Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, New York, US

**Magdalena Thurin**

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, Maryland, US

**Tara Withington**

Executive Director of Society of Immunotherapy for Cancer (SITC), Milwaukee, Wisconsin, US

# FACULTY

**Sanjiv S. Agarwala**

Professor & Chief, Haematology & Oncology, St Luke's University Hospital and Temple University, Bethlehem, PA, US

**Paolo A. Ascierto**

Director, Medical Oncology, Melanoma, Cancer Immunotherapy and Development Therapeutics Unit, National Cancer Institute Fondazione "G. Pascale", Naples, Italy

**Michael B. Atkins**

Deputy Director & Professor Acting Chief, Division of Hematology/Oncology MedStar Georgetown University Hospital, Georgetown University Medical Center, Washington, DC, US

**Christian Blank**

Medical Oncology and Research Group Leader Tumor Immunology, Netherlands Cancer Institute, Amsterdam, The Netherlands

# FACULTY

---

**Gerardo Botti**

Scientific Director National Cancer Institute "Fondazione G. Pascale" Naples, Italy

**Corrado Caracò**

Director of Melanoma and Skin Tumor Surgery, National Cancer Institute "Fondazione G. Pascale", Naples, Italy

**Richard D. Carvajal**

Director of Experimental Therapeutics and Director of the Melanoma Service, Columbia University Medical Center, New York, NY, US

**Reinhard Dummer**

Professor of Dermatology, University of Zurich Hospital, Department of Dermatology, Zurich, Switzerland

**Alexander Eggermont**

Professor of Oncological Surgery and General Director, Institut Gustave Roussy Villejuif, Paris-Sud, France

**Marc Ernstoff**

Branch Chief of ImmunoOncology Branch (IOB), Developmental Therapeutics Program, Division of Cancer Therapy & Diagnosis, NCI, NIH, Bethesda, MD, US

**Soldano Ferrone**

Department of Surgery Massachusetts General Hospital, Harvard Medical School, Boston, MA, US

**Bernard A. Fox**

Chief of Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center in the Earle A. Chiles Research Institute at Providence Cancer Center, Portland, OR, US

**Thomas F. Gajewski**

Oncology and Immunology Professor, Department of Pathology and Department of Medicine (Section of Haematology/Oncology) - University of Chicago (Microbiome Center), Chicago, IL, US

**Jerome Galon**

Research Director, National Institute of Health and Medical Research (INSERM), Paris, France

**Claus Garbe**

University Professor of Dermatology, Division of Dermatologic Oncology Department of Dermatology, Eberhard-Karls University Tuebingen, Germany

**Jeffrey E. Gershenwald**

Professor, Department of Surgical Oncology, Division of Surgery, The University of Texas, MD Anderson Cancer Center, Houston, TX, US

**Jean-Jacques Grob**

Professor, Head of Dermatology Department, Hopital de la Timone, Aix-Marseille, Marseille, France

**Omid Hamid**

Director, Clinical Research and Immunotherapy The Angeles Clinic and Research Institute, Los Angeles, CA, US

**Patrik Hwu**

MD, President & CEO, Moffitt Cancer Center, Tampa, Florida, US

**Pawel Kalinski**

Vice Chair for Translational Research, Department of Medicine, Director of Cancer Vaccine and Dendritic Cell Therapies, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, NY, US

**Michelle Krogsgaard**

Associate Professor of Pathology, New York University Langone, Medical School, New York, NY, US

**Roger Lo**

Melanoma Clinic in Dermatology Member, Jonsson Comprehensive Cancer Center David Geffen School of Medicine at UCLA, Los Angeles, CA, US

**Georgina V. Long**

Co-Medical Director Melanoma Institute Australia, Professor of Melanoma Medical Oncology and Translational Research Melanoma Institute Australia, The University of Sydney and Royal North Shore Hospital, Sydney, Australia

# FACULTY

---

**Jason J. Luke**

Director of the Cancer Immunotherapeutics Center of UPMC Hillman Cancer Center; Associate Professor of Medicine at the University of Pittsburgh, Pittsburgh, Pennsylvania, US

**Giuseppe Masucci**

Professor, Department of Oncology-Pathology, Karolinska Institute, Stockholm, Sweden

**Olivier Michielin**

Analytical Oncology Division Director, Oncology Department UNIL-CHUV, Lausanne, Suisse

**Paul Nathan**

Consultant Medical Oncologist, Mount Vernon Cancer Centre, Northwood, Middlesex, UK

**Bart Neyns**

Head of department, Medical Oncology, Universitair Ziekenhuis Brussel, Brussel, Belgium

**Iman Osman**

Associate Dean for Translation Research and Director of the Melanoma Program, New York University Langone, Medical School, New York, NY, US

**Giuseppe Palmieri**

President Italian Melanoma Intergroup (IMI), Head of Unit of Cancer Genetics, Institute of Biomolecular Chemistry (ICB), National Research Council (CNR), Sassari, Italy

**Michael A. Postow**

Memorial Sloan Kettering Cancer Center, New York, NY, USA

**Igor Puzanov**

Director, Early Phase Clinical Trials Program, Chief of Melanoma, Co-Leader, CCSG Experimental Therapeutics Program, Professor of Oncology, Department of Medicine, Roswell Park Comprehensive Cancer Center, Developmental Therapeutics, Buffalo, NY, US

**Sergio Quezada**

Professor of Cancer Immunology and Immunotherapy, Group Leader of Cancer Immunology Unit, Research Department of Hematology, Cancer Institute, University College London, London, UK

**Vernon K. Sondak**

Chair & Professor, Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, US

**Jeffrey A. Sosman**

Professor, Medicine, Hematology Oncology Division, Feinberg School of Medicine, Northwestern University, Chicago, IL, US

**Hussein A. Tawbi**

Associate Professor, Director of Melanoma Clinical Research & Early Drug Development, Melanoma Medical Oncology, Investigational Cancer Therapeutics, UT MD Anderson Cancer Center, Houston, TX, US

**Michele Teng**

Associate Professor, Head of the Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Brisbane, Australia

**Alessandro Testori**

Fondazione IRCCS Policlinico San Matteo, Pavia, Italy & chairman surgical subgroup EORTC Melanoma Group Brussels

**Magdalena Thurin**

Program Director, Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCI, NIH, Rockville, MD, US

**Giorgio Trinchieri**

NIH Distinguished Investigator, Chief, Laboratory of Integrative Cancer Immunology (LICI) Center for Cancer Research, NCI, NIH, Bethesda, MD, US

**Jeffrey S. Weber**

Deputy Director, Professor of Oncology, Department of Medicine, Perlmutter Cancer Center, New York University Langone, Medical School, New York, NY, US



# E.C.M.

*Commissione Nazionale Formazione Continua*



## CONTINUING MEDICAL EDUCATION

3P Solution has been accredited by the Ministry of Health as a CME Standard Provider (code 327, authorized on October 15th, 2012).

3P Solution owns the responsibility for the content, quality and ethical correctness of this CME activity.

Melanoma Bridge congress has been accredited (ID CME 327-307144) with 19,5 CME credits with a formative technical-professional objective "Technical professional content (knowledge and competences) specifications of each profession, of all specialization and ultra-specialist activity. Rare disease", belonging to formative technical-professional objective area, for the following professions: medical doctors, pharmacists, biologists, nurses.

The number of attendees can not exceed the number of accredited participants.

In order to receive credits, participants must:

1. Attend at least 90% of the accredited CME sessions (attendance check);
2. Complete the CME test by answering at least 75% of the questions correctly;
3. Complete the evaluation form.

## MY ECM

Age.na.s activated MyEcm service (personalized page available to any health professional), which enables you to:

1. Consult the CME events offer;
2. Refer to the summary of events attended and earned credits;
3. Provide an assessment of courses organized by the Provider.

To access online services please log on to <http://ape.agenas.it/professionisti/myecm>.

If this meeting fulfilled your expectations, please click on  and give your assessment.

Immunotherapy Bridge is sponsored by an unrestricted grant from:

---

**PLATINUM SPONSOR**



**GOLD SPONSOR**



**SILVER SPONSOR**



Celebrating 30 Years in Europe

**SPONSOR**



IMMUNOCORE

